peptide wiki

Mechanism

Pre-mixed three-peptide blend marketed for tissue repair and recovery, combining BPC-157 (a synthetic gastric-pentapeptide fragment), TB-500 (a synthetic Thymosin β4 fragment that promotes actin regulation and cell migration), and Cartalax (a synthetic Lys-Glu-Asp tripeptide, AED-related, marketed for cartilage and connective-tissue support). Each component is an individually grey-market research compound with no FDA-approved human indication; the blend itself has no published controlled human efficacy or safety data. Any rationale is inferred from preclinical and uncontrolled reports on the separate peptides, and combination-specific human data is lacking.

Studied uses

• Marketed (research only) for tendon, ligament and soft-tissue repair
• Marketed (research only) for cartilage and joint recovery support
• Claimed acceleration of wound and injury healing

Identification

Typical dose	No validated blend protocol exists. Vendor norms for the components: BPC-157 250–500 mcg/day subcutaneous; TB-500 2–5 mg/week subcutaneous; Cartalax 1–2 mg/day subcutaneous or intranasal. Research use only.
Half-life	Component-dependent and not characterized for the mixture. BPC-157: disputed (minutes to ~4 hours, subcutaneous); TB-500: ~2 hours plasma; Cartalax: short peptide half-life, not well characterized in humans.

Safety

Not FDA-approved in any form; sold as a research/grey-market compound. No combination-specific human safety data; the long-term and interaction safety profile of the three peptides together is unknown. Purity and content of grey-market blends are unverified absent a third-party COA.